#United States #Emeryville #Flow Cytometry #Slingshot Biosciences #Nimisha Srivastava

Slingshot Biosciences Welcomes New Leadership

In a significant move for the future of Slingshot Biosciences, the company has announced the appointment of Dr. Nimisha Srivastava as its new Chief Executive Officer (CEO), effective September 23, 2026. As a prominent player in the field of precision-engineered synthetic cell mimics used in flow cytometry, Slingshot is set for an exciting new chapter under Dr. Srivastava’s experienced leadership.

Dr. Srivastava, who previously served as the Chief Operating Officer, is well-regarded for her integral role in the company's strategic implementation and operational excellence. Her promotion comes as a result of Glenn Bilawsky transitioning out of the CEO role, who is thanked by the Board for his contributions during his tenure. Nicolas Barthelemy, the Chairman of the Board, expressed confidence in Dr. Srivastava's abilities, stating, "Her deep understanding of our technology and its applications will enable her to lead the company effectively into its next phase."

The transition in leadership aligns with Slingshot's ongoing commitment to strengthen its presence in the market, particularly in advancing its innovative product portfolio, and fortifying customer relationships. Dr. Srivastava emphasized her excitement regarding the new position, saying, "I am honored and humbled to take on the role of CEO, and I am grateful to the Board for its confidence in me. My focus will remain on developing our business while bringing innovative products to market."

Dr. Srivastava's background in pioneering technologies adds significant value to her new role. Before joining Slingshot, she was part of the founding engineering team at Twist Bioscience, where she was instrumental in scaling up various laboratory processes and automating synthetic DNA and RNA production. Her wealth of experience positions her well to lead Slingshot in pioneering its core mission: eliminating the inconsistency associated with traditional biological reference materials.

Currently, Slingshot Biosciences specializes in providing scalable and customizable solutions for flow cytometry that produce reliable results, thereby enhancing the integrity of biological analyses. As the company continues to push boundaries in cell therapy, drug development, and diagnostics, Dr. Srivastava will steer these initiatives toward successful implementation.

Looking forward, the strategic focal points under Dr. Srivastava’s guidance will include bolstering commercial growth and advancing new product developments that resonate with Slingshot’s clientele and stakeholders. The leadership transition is not just about a change in faces; it reflects an unwavering focus on continuity and precise execution of core strategies already in place. The new CEO is committed to shaping the strategy while ensuring that the company retains its mission-oriented culture.

In summary, Slingshot’s transition in leadership heralds a robust future for the company. With Dr. Srivastava at the helm, stakeholders can expect an energized approach to enhancing product development, customer engagement, and the overall growth of the company in the evolving landscape of synthetic biology.

For further information regarding Slingshot Biosciences and its innovative contributions to the biotech industry, interested parties are encouraged to visit slingshotbio.com.